mHealth and Telemedicine Innovation Vastly Improving Healthcare Services for Patients - Seite 2

"NextGen's partnership with Reliq Health will allow us to utilize their existing mHealth platform to provide a novel, innovative mobile healthcare solution to the citizens of San Antonio and surrounding area," said a spokesperson of NextGen Applications. "The resulting mTelecare mobile app will provide a telemedicine platform that connects patients to doctors and nurses anywhere where there is internet access. mTelecare will support secure video consults for patients with doctors and nurses, providing patients with professional care from the comfort of their own home. The mTelecare app will also provide automated prescription refills, search tools for healthcare services, a personalized health calendar with push notifications, reminders and a suite of billing and payment tools. mTelecare will provide greater access to healthcare, while at the same time reducing healthcare costs."

Reliq Health Technologies is also pleased to announce that it will be hosting a investor call on December 1, 2017 at 8:00am PST/11:00am EST. Please visit the Company's website (http://www.reliqhealth.com) the week of November 20, 2017 for call in details and information on how to submit your questions electronically in advance of the call.

In other Healthcare Industry developments: 

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, the week reported financial results for the third quarter ended September 30, 2017, and provided an update on recent achievements and upcoming events. "This was a quarter of continued steady progress in advancing our pipeline of CRISPR medicines toward the clinic," said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. "We were pleased to announce that we initiated our clinical natural history study for our lead program to treat LCA10, and we remain on track to file our IND for EDIT-101, our clinical candidate, in mid-2018. In addition, we look forward to data that will be presented at the upcoming meetings of the Society for Immunotherapy of Cancer and American Society of Hematology from a range of our wholly-owned and partnered engineered cell therapy programs."